Dear Friend,

Through its partnership with the Division of Pediatric Hematology and Oncology at NewYork–Presbyterian Hospital/Weill Cornell Medical Center, the Children’s Cancer and Blood Foundation has worked for over 65 years to support comprehensive and compassionate clinical care, to foster cutting-edge research breakthroughs and to train the next generation of leaders in the pediatric hematology and oncology field.

We hope that this 2018 Annual Report will give you a window into the amazing things happening at our Division. Every day, clinicians at the Division implement new and better treatment protocols; art therapists, social workers and child life therapists tend to the emotional needs of patients and families; and researchers seek cures.

As survival rates increase, new prerogatives are emerging. Our Division now has programs focused on our patients’ long term health needs, including fertility preservation. We are not only saving children, but offering hope of long, full lives.

Your support makes all of these things possible. Thank you!

With gratitude,

Les Lieberman  Ron Iervolino  Drew Phillips
Through its support of the Division, CCBF has created a standard of excellence in the treatment of children with chronic, life threatening cancer and blood diseases.

HISTORY

1944
Carl H. Smith, a physician and researcher, starts the Children’s Blood Transfusion Clinic at New York Hospital. This clinic, the first of its kind in the United States, treated children with thalassemia, a life threatening blood disease.

1952
Dr. Smith partners with Harold Weill to found the Children’s Blood Foundation, an organization supporting research in the underfunded area of children’s blood disorders.

1997
The Children’s Blood Foundation’s home at New York Hospital merged with Presbyterian Hospital to become New York Presbyterian Hospital/Weill Cornell Medical Center.

2006
The Children’s Blood Foundation changed its name to the Children’s Cancer & Blood Foundation (CCBF) to reflect its commitment to treating the entire patient population of the Division of Pediatric Hematology and Oncology.

TODAY
Through its support of the Division, CCBF has created a standard of excellence in the treatment of children with chronic, life threatening cancer and blood diseases.
MISSION

With support from CCBF, the Division is revolutionizing the way we understand and treat childhood cancer and blood diseases.

CCBF support ensures that children and their families receive state-of-the-art, comprehensive care in an atmosphere of compassion and hope.

By supporting specialty training of young physicians who are pursuing a practice in pediatric hematology and oncology, CCBF is making cures possible for generations to come.

RESEARCH

CARE

CURE

IMPACT

CCBF is funding brighter futures through its support of groundbreaking research in pediatric hematology and oncology at the Division. Thanks to the development of new medications and treatment strategies for many childhood cancers and blood diseases, our young patients are living longer than ever before.

As survival rates increase, the quality of life for these survivors has become an increasing concern—and an important part of our new programs, such as long-term survivorship care and fertility preservation. We aim not only to treat these young patients, but to return them to lives that are as normal and productive as possible.
PATIENT SPOTLIGHT

Peyton, 3 years old
Within minutes of meeting Peyton, you can guess that dancing, singing, and hugs are on her list of favorite things.

Peyton came to the Division the night of December 14th, 2018 and was diagnosed with acute lymphoblastic leukemia two days later. She was referred to the Division for a bone marrow biopsy after a doctor in a different hospital saw signs indicating leukemia. Peyton’s story is an example of how many patients are referred to the Division, as pediatricians throughout New York City know that the Division has the specialists and resources to care for patients with these diseases.

When asked about their experience at the Division, Peyton’s parents couldn’t say enough great things about the staff and the atmosphere of hope and healing they foster. The staff have gone above and beyond in many ways, including nominating Peyton for the Kleinfield Bridal fashion show, working the playroom schedule so she can play even when her treatment requires her to stay in isolation, and making sure that her daily wish for yellow socks is met.

Everyone in the clinic knows Peyton because of the way she lights up the room when she enters, but Peyton has a special bond with the Division’s art therapist, Jackie. Jackie is the first person Peyton looks for when she arrives, and Peyton’s parents refer to Jackie as “heaven-sent” for the way she plays with Peyton and nurtures her creativity and playfulness, even in the face of this fight.

"The first person she looks for is Jackie the art specialist." – Sanayia, Peyton’s mom

PATIENT SPOTLIGHT

Ananya, 17 years old
When Ananya’s family moved to Manhattan a number of years ago, one of their concerns was where she would continue her treatment for hemoglobin E beta thalassemia. They came to Weill Cornell Medical Center because of the Division’s unique ability to care for this condition.

Ananya, now 17, has been treated at the Division for seven years, and has many accolades for the staff at the Division. Ananya emphasized that she is grateful for the way in which Dr. Sheth has been a supportive advocate for her, and has helped her to ensure that she and her parents are on the same page as far as her treatment protocols. In between these weighty conversations, Ananya appreciates the laughs and smiles she’s shared with Jo, one of the Division’s phlebotomists.

The child life and art therapy programs in the hospital have been extremely helpful to Ananya and her family. Frequent trips to the hospital are a burden on a young patient and their family. Ananya notes that doing art projects while talking to staff who listen distracts her from her medical procedures, and helps her enjoy the hours spent at the Division. Ananya also mentions that the arts and crafts program provides a welcome diversion for her younger sister, who must often accompany her to the hospital.

"Dr. Sheth has been a really supportive advocate for me" – Ananya
Here are just a few of the projects our scientists are working on:

Laboratory Research

- Dr. David Lyden is working to understand the role of tumor cell-derived “packages” called exosomes in cancer metastasis. By characterizing the exosomes, our scientists hope to be able to determine which cancers will spread—and to where.
- Dr. Lisa Roth is studying the factors that lead to the development of lymphoma, with the goal of developing therapies that can target specific steps in this developmental cascade.
- Dr. Nicole Kucine is studying genetic factors causing rare disorders in children called myeloproliferative syndromes.

Clinical Research Initiatives

- Individuals with thalassemia develop transfusional iron overload, and the iron may be deposited in organs and cause complications. The Comprehensive Thalassemia Program has focused on research related to defining the iron levels in the tissues and studying chelation therapy. The goal of chelation therapy is to effectively remove iron which has been deposited and prevent more from accumulating.
- The Hemophilia Treatment Center is participating in trials of newer agents to ameliorate and prevent bleeding in hemophilia patients, including potentially curative gene therapy approaches.
- The Platelet Disorders Program is studying factors which predispose children to have a more chronic pattern of disease, with the goal of predicting this at diagnosis.
- Through the Onco-Fertility Program, our clinicians identify patients at high risk of impaired fertility from chemotherapy and offer fertility-preserving approaches.
- In conjunction with the Adolescent and Young Adult Lymphoma Program, our researchers are designing targeted therapies that may have less toxicity than traditional chemotherapy for Hodgkin and non-Hodgkin lymphoma.
**OUR DOCTORS**

Dr. Sheth leads the Comprehensive Thalassemia Center, which is one of the largest in the United States and is designated as a hemoglobinopathy specialty center by the New York State Department of Health. Thalassemia is a genetic condition that stops patients from making normal hemoglobin (red blood cells). Without regular transfusions of hemoglobin, this condition is terminal. However, over time the transfusions put patients at risk of death from iron overload. Dr. Sheth is involved in studies of chelation (ways to remove iron), as well as studies of better ways to manage treatment, including stem cell transplantation and gene therapy. Dr. Sheth also treats other congenital anemias, and has helped develop new therapies such as luspatercept in pyruvate kinase deficiency.

**SUJIT SHETH**
HEAD OF DIVISION
THALASSEMIA

---

Dr. Aledo is the Director of the Pediatric Oncology Program. He has been an attending physician at Weill Cornell Medical Center for over 25 years, and is experienced in treating and managing all forms of childhood cancer. In addition, he is the Division’s Principal Investigator for the Children’s Oncology Group (the world’s largest organization devoted exclusively to pediatric cancer research), and therefore ideally situated to use COG protocols across a variety of diseases, and to implement the complicated treatments that are so essential to survival in children.

**ALEX ALEDO**
PEDIATRIC ONCOLOGY

---

Dr. Lisa Roth specializes in treating children with lymphoma and leukemia. Dr. Roth, a lymphoma survivor herself, is world renowned for her work in finding new therapies for lymphoma. Her clinical activities with the Children’s Oncology Group network have explored novel treatments and randomized studies to best define the treatment of lymphomas, establishing new national protocols. She also founded the Adolescent and Young Adult Lymphoma Program, where she now serves as director. This program focuses on delivering comprehensive care to young lymphoma patients and their families. The program is leading national research initiatives to understand more about lymphoma in young people, and to help identify new and better therapies.

**LISA GIULINO ROTH**
LYMPHOMA AND LEUKEMIA
Dr. Kaicker, who was previously at Maimonides in Brooklyn and St. Joseph’s in Patterson, is the newest member of the Division. Dr. Kaicker has extensive clinical experience and runs both the Sickle Cell Disease Program and the Platelet Program. She liaises with the adult sickle cell disease program at Cornell, and will be taking advantage of the NY Presbyterian-Weill Cornell hospital network to implement the latest advances in the management of sickle cell disease.

Dr. Kucine is a national expert in pediatric myeloproliferative neoplasms, a disease in which patients have elevated blood counts but do not have leukemia. This is a disease that occurs most commonly in adults; as a result, diagnosis and management of pediatric cases has historically not been well understood. Dr. Kucine has a five-year National Institute of Health grant, allowing her to focus on extensive molecular studies to try to best understand what drives these cases and whether pediatric cases are different than adult cases. She is also exploring the extent to which children can be treated with the same protocols as adults.

By 2020, there are projected to be more than 500,000 survivors of childhood cancer in the United States. Survivors need specialized care to help manage the long term risks of their treatments. Dr. Levine, who specializes in the treatment of leukemia, directs the team that provides long-term follow-up care for survivors of childhood and adolescent cancers. Dr. Levine has a special interest in the effects of chemotherapy on fertility, with a research focus on identifying patients most at risk of impaired fertility so they can be offered fertility-preserving approaches. Dr. Levine has been active in helping to standardize national guidelines for fertility preservation for children, adolescents and young adults.
Dr. Lyden, who has been at the Division for his entire career, is a leading national cancer researcher. Dr. Lyden has devoted his career to studying the process of cancer metastasis and, as a result, has made ground breaking discoveries about the way that cancer spreads. Dr. Lyden’s work first showed that cancerous cells send out very small particles called exosomes, which direct other cells to go to the site of intended metastasis and create a "nest". When the nest is ready, the cancer cell can travel there and take up residence. He is a Nobel lecturer and was a 2018 recipient of the National Institute for Health Outstanding Investigator Award and the Weill Cornell Siegal Family Research Award.

Dr. McGuinn is in charge of the Hemophilia and Bleeding Disorders Program, a longstanding area of expertise in the Division. She is actively involved in the latest treatment protocols. New protocols include gene therapy for adeno-associated viruses, a treatment developed in collaboration with one of our former residents who is now at the Children’s Hospital of Philadelphia. This work was recently published in the New England Journal of Medicine. Dr. McGuinn also runs the joint fellowship program with Memorial Sloan Kettering, which trains six fellows per year.
Hundreds of prominent New Yorkers came together at the Plaza Hotel on November 27th, 2019 to rally around CCBF’s mission at our annual Breakthrough Ball. Pearl Koch, 11-year-old survivor of non-Hodgkin lymphoma, and her family were honored and received the Breakthrough Spirit award at this year’s gala. Dr. Lisa Roth, Pearl’s physician and a survivor of non-Hodgkin lymphoma herself, was also honored at the event. Emcees Ashleigh Banfield and Greg Kelley guided the guests through a lively evening of fun and philanthropy.

Dr. Roth reflected on the significance of being diagnosed with the very disease she had spent much of her career researching. She noted that the advances in care and treatment between when she was diagnosed and when Pearl was diagnosed in 2018 are massive, but that there is still work to do. Guests enjoyed a live performance by Swedish pop duo Icona Pop, who are widely known for their hit single "I Don't Care."

2018 Breakthrough Spirit Award recipients pose for a photo
From left to right: Dr. Lisa Roth, Pearl Koch, Nicole Koch, Danny Koch, Hazel Koch

Swedish pop duo Icona Pop performs at the 2018 Breakthrough Ball

CCBF donors and Board members enjoy an electrifying performance from Icona Pop
IN OUR COMMUNITY

RACE AGAINST CANCER

Sylvan Henry, ultramarathoner and dad from Brooklyn, had a reason for running this year’s TCS New York Marathon that went beyond fitness. He used his training as an opportunity to raise money and awareness for CCBF!

HOLIDAY CHEER

For many, the holidays are a time full of joy, family, and fun. CCBF strives to make sure that this is true for the patients and families at the Division as well.

This year’s events included a holiday party at the Division (above), a college student run toy drive (right), and our annual Toys for Tots party.

KIDS CARING FOR KIDS

It truly is never too early to start making a difference. Hugo from Ardsley, NY used his seventh birthday as a way to raise money for CCBF. He was able to raise and make a donation of over $100 towards our mission!
### Statement of Revenues and Expenses
Year ending December 31, 2018

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Support</td>
<td>470,221</td>
</tr>
<tr>
<td>Expenses</td>
<td></td>
</tr>
<tr>
<td>Program Services</td>
<td>981,093</td>
</tr>
<tr>
<td>Management</td>
<td>204,248</td>
</tr>
<tr>
<td>Fundraising</td>
<td>24,185</td>
</tr>
<tr>
<td>Total Expenses</td>
<td>1,209,526</td>
</tr>
</tbody>
</table>

### Balance Sheet

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash</td>
<td>492,615</td>
</tr>
<tr>
<td>Investment At Market</td>
<td>4,105,163</td>
</tr>
<tr>
<td>Pledges Receivable</td>
<td>97,473</td>
</tr>
<tr>
<td>Other</td>
<td>29,384</td>
</tr>
<tr>
<td>Total Assets</td>
<td>4,724,635</td>
</tr>
<tr>
<td>Total Liabilities</td>
<td>29,998</td>
</tr>
<tr>
<td>Net Assets</td>
<td>4,694,637</td>
</tr>
</tbody>
</table>

### Expense Distribution

**Program Services**
These are the clinical care, research, and educational program grants that CCBF provides to the Division of Hematology and Oncology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

**Management**
These are costs related to administering the day-to-day activities at CCBF.

**Fundraising**
These are costs related to appeals for financial support.
HONOR ROLL OF DONORS

$50,000+
Sy Syms Foundation
Trish and Ron Iervolino

$25,000–$49,999
John F. O’Donnell
Liz and David Sherman
Laurie and James Quigney
Timothy Myers
Carolyn and Malcolm Wiener
Denise LeFrak and Mr. John Calicchio
The Taft Foundation
Wachtell, Lipton, Rosen & Katz
Norma and Edward Munves

$10,000–$24,999
The Rachel & Drew Katz Foundation
Jessica and Drew Phillips
Susan and Lewis Wirshba
Florida Community Bank
Hilary and Stuart Oran
Barbara and Michael Kowalski
Kim and Ivan Zinn
Joanne and Michael LoBosco
Pink Pony Fund
Daniel & Mary Reeves Foundation
Ivan Obolensky
Chriissy and Andrew Springer
Josephine Lawrence Hopkins Foundation
Jon & Mindy Gray Family Foundation
Atlantic Records
Suzanne Dreifuss and Marc Hurwitz
Jasper Johns

$5,000–$9,999
Aram and Sherry Azadi Moezinia
Josefow Foundation
Susie and Paul M. Friedman
Suzanne and Jonathan Davis

$1,000–$4,999
David C. Lyden
Scott Sherman
Janet and Thomas Constance
Peter Chieco
Laurie and Arthur Malman
Thomas & Jeanne Elmezzi Foundation
Linda KrechTZowski
Melissa Bliski and Chris Mayer
Roberta and Eugene Wells
Greater Talent Network Inc.
Mary Graci
Joy Garnett
Pacific Resort Aitutaki, Cook Islands
Massimo
New York Jets
Fiona Dodd Simmonds
BNY Mellon/The Ferriday Fund Charitable Trust
Melissa and Bruce Fischer
Brooke and Michael Santulli
Day and George Watson
Superior Biologics, Inc.

Jane Martin and Stuart Katz
CBRE
Gilead Hausner Jewish Day School
Lisa and Russell Middleton
Arlene Graci
Gerald H. Blum
UBS Financial Services Inc.
Jennifer Zaleski and Phil Fortino
Heather and Todd Kushner
Charlotte Cunningham-Rundies and James B. Bussel
Wonderful Giving
Shire Human Genetic Therapies, Inc.
Blank Aschkenasy Properties LLC
Dennis Connors
Shelley and Murray Stoltz
Bruce Horton and Aaron Lieber
Ellen and John A. Walsh
Joanna and Bruce McDermott
New York–Presbyterian
Robyn Tamofsky and Antony Ryan
Eliza Carametar and Jim McCann
Christine and Frank Carcione
Margaret and Douglas Bateson
Emily and Vincent Loiacono
Lynne and George Fina
Joan McClure and Michael Schler
Riyadh and Kasia Janczura Mohammed
Jacqueline and Alan Mitchell
Robyn Lane Joseph and Ken Joseph
Karyn Kornfeld and Steven Kobere
Sujit Sheth
Ruscha Revocable Trust
Havde Financial, Inc.
Anand Gajjar
Arlene and Harry C. Schell, III
John Garvey Foundation
Lauren and Scott Nussbaum
Lev Vinogradov
Metropolitan Golf Writers Association
Robin Roberts
Madden Charities
Franklyn L. Lifsky
Ravi and Saran Trehan
Fairmont Kea Lani, Maui
Jingle Ball – NYC
Le Bristol Paris
NFL / SuperBowl
Fairmont Royal Pavilion, Barbados
Gibson Foundation
Banyan Tree Hotels & Resorts
Bulgari Hotel Milan
Tristan Watt and Grier Eliasek
The Greenwich Hotel
Trump National Golf Club
Cynthia Rowley
MLB / NY Mets
New York Knicks

Children’s Cancer & Blood Foundation | Page 14
New Jersey Devils
Ritz-Carlton Moscow
Luxury VIP Suites
DANIEL, NYC
I Palazzone
Chelsea Frames
Di MODOLO Milano
The Ritz-Carlton, Lake Tahoe
Philadelphia 76ers/NBA
Fairmont Chicago, Millennium Park
Fairmont Hotel Macdonald, Edmonton
Shops at Columbus Circle
Jingle Ball – NYC
The Plaza Hotel
WestJet
Intercontinental Montreal

$500–
$999
Tristana Waltz and Grier Eliasek
Lauren LeBlanc
Vijay Prabhakar
Robert Grady
Alexander Navab
Hilary and Stephen Blumenreich
JPMorgan Chase & Co.
David Lei
James L Buttenwieser
Jolie Schwab and David Hodes
Helen Nitkin
Lynn and Thomas Skea
Mary and John Iacuzzo
Barbara and Gerald M. Loughlin
Holly Phillips and Jose Tavarez
Tina and Phillip DeLeonardis
Debbi and Lawrence H. Rosati
Pier and George T. Lowy
Marlene Dann
Mitchell Gallo
Marcie and Douglas Heymann
Penn Quad Foundation, Inc.
Arthur E. Eisman
Elizabeth Grayer and Aidan Synnott
Christina and Patrick O’Rourke
Janice and Martin Leyton
Israeli Pediatric Brain Tumor Foundation
Bert N. Mitchell Family Foundation
Janna Raskop
Christopher Berman
R. Bruce Cameron
Robert Ley
The Ann Liguori Foundation

And so many others who have moved our mission forward throughout the years!
CCBF LEADERSHIP

Directors

Les J. Lieberman
Co-Chairman

Ronald J. Iervolino
Co-Chairman

Drew Phillips
President

Janice Garjian
Secretary

David Sherman

Deborah Gelston

James B. Bussel, M.D.

Isabel B. Kallman

John Calicchio

John F. O’Donnell

Jonathan D. Davis

M. Reza Raein

Nancy Shaw

Patricia J. Giardina, M.D.

Peter G. Smith

Robbin Mitchell

Stuart Oran

Tristana Waltz

Medical Advisors

Sujit Sheth, M.D.
Chief,
Division of Pediatric Hematology and Oncology

Gerald M. Loughlin, M.D.
Chair,
Department of Pediatrics
Approximately 1 in 285 kids in the US will be diagnosed with cancer before their 20th birthday.

Each year, hundreds of children receive treatment at the CCBF Division, and countless children around the world benefit from the research breakthroughs being made by our faculty, both in the lab and in the clinic.

The five-year survival rate for pediatric cancer has increased from 58% to 84% since the 1970s.

WAYS TO GIVE

Visit childrenscbf.org to donate online.

Call 212-297-4336 to donate via phone.

Speak with your attorney about leaving CCBF a gift in your will or living trust. We are happy to answer questions.

If you wish to send a check, send it to 466 Lexington Ave 16 Fl, New York, NY 10017.

Many companies match the gifts made by their employees. Speak with your HR department to find out if they match.

Only 4% of federal government cancer research funding goes to study pediatric cancer.

Mortality and hospitalization rates for bleeding complications from hemophilia are 40% lower among people who received care in hemophilia treatment centers like the Division.

Many children with sickle cell disease do not receive the necessary care.

The CDC estimates that only 1/3 of children with SCD receive appropriate monitoring for stroke risk.